{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:58:15Z","timestamp":1778428695935,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clinthera.2020.05.022","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T01:46:44Z","timestamp":1596073604000},"page":"1519-1534.e33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1726-5198","authenticated-orcid":false,"given":"Bruce A.","family":"Hug","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-2173","authenticated-orcid":false,"given":"Christopher J.","family":"Matheny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Struemper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6174-0550","authenticated-orcid":false,"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9497-2163","authenticated-orcid":false,"given":"Michael L.","family":"Washburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.05.022_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2020.05.022_bib2","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2174\/0929867324666170320114359","article-title":"Recent findings on the application of Toll-like receptors agonists in cancer therapy","volume":"24","author":"Mikulandra","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clinthera.2020.05.022_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-981-10-5987-2_9","article-title":"TLR agonists as adjuvants for cancer vaccines","volume":"1024","author":"Li","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clinthera.2020.05.022_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1534735416649916","article-title":"Coley's lessons remembered: augmenting mistletoe therapy","volume":"15","author":"Orange","year":"2016","journal-title":"Integr Cancer Ther"},{"key":"10.1016\/j.clinthera.2020.05.022_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1526250","article-title":"Trial Watch: Toll-like receptor agonists in cancer immunotherapy","volume":"7","author":"Smith","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clinthera.2020.05.022_bib6","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1039\/C8AY00571K","article-title":"Development of an ultra-sensitive assay for the determination of an aminoalkyl glucosaminide 4-phosphate, GSK1795091, in plasma to support a first time in human study","volume":"10","author":"Licea-Perez","year":"2018","journal-title":"Anal Methods"},{"key":"10.1016\/j.clinthera.2020.05.022_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.12055","article-title":"Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy","volume":"36","author":"Gao","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.05.022_bib8","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.clinthera.2020.05.022_bib9","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"1996"},{"key":"10.1016\/j.clinthera.2020.05.022_bib10","author":"World Medical Association"},{"key":"10.1016\/j.clinthera.2020.05.022_bib11","first-page":"28","article-title":"Characterization of inflammation and immune cell modulation induced by low-dose LPS administration to healthy volunteers","volume":"11","author":"Dillingh","year":"2014","journal-title":"J\u00a0Inflamm"},{"key":"10.1016\/j.clinthera.2020.05.022_bib12","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/0959-8049(96)00186-4","article-title":"Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer","volume":"32A","author":"Otto","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2020.05.022_bib13","author":"Food and Drug Administration"},{"key":"10.1016\/j.clinthera.2020.05.022_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/cpt.157","article-title":"Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: use of translational biomarkers to guide dosing and confirm target engagement","volume":"98","author":"Tsitoura","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2020.05.022_bib15","first-page":"397","article-title":"Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide","volume":"6","author":"de Bono","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2020.05.022_bib16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2407-13-172","article-title":"Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors","volume":"13","author":"Isambert","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2020.05.022_bib17","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1128\/AAC.48.9.3233-3240.2004","article-title":"Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers","volume":"48","author":"Rossignol","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.05.022_bib18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0016-5085(95)90765-3","article-title":"Role of hepatocytes in direct clearance of lipopolysaccharide in rats","volume":"109","author":"Mimura","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2020.05.022_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cyto.2013.04.014","article-title":"Low dose LPS does not increase TLR4 expression on monocytes in a human in\u00a0vivo model","volume":"63","author":"Lichte","year":"2013","journal-title":"Cytokine"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:23Z","timestamp":1758963203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820302861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0149291820302861"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 GlaxoSmithKline. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}